Biomedical subjects

M F Peake

Publications and source records attributed to M F Peake.

4 recordsLinked to original sources

PubMed1998

Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin.

We report the case of a woman from the Bahamas who presented with many of the classic manifestations of dermatomyositis. She responded well to initial therapy, which included oral corticosteroids, low-dosage methotrexate, and hydroxychloroquine. The cutaneous component of her disease flared dramatically months later, and progressed despite aggressive therapy with the higher dosages of the same medications. Therapy with intravenous immunoglobulin (IVIG) was initiated and the patient stopped forming new cutaneous ulcers within 1 to 2 weeks. Theories about the mechanism of action of IVIG, and practical guidelines for its use in treating patients with dermatomyositis, are briefly reviewed.

Dermatologic Agents↗

PubMed1997

'Dimpling' is not unique to dermatofibromas.

The dimpling of the skin with lateral compression or 'Fitzpatrick's sign' is considered by many to be pathognomonic for dermatofibromas (DFs). Despite the description of this sign in all major textbooks, not all DFs dimple and all that dimple are not DFs. Other diagnostic investigations such as the use of dermatoscopy may help to confirm the clinical suspicion of DF.

Biopsy↗

PubMed1996

Paclitaxel-induced radiation recall dermatitis.

The authors present a case of radiation recall dermatitis occurring in a patient receiving paclitaxel shortly after completion of radiation therapy. A brief review of previously reported taxane-induced radiation recall reactions is provided.

Antineoplastic Agents, Phytogenic↗

PubMed1996

Hepatitis C and porphyria cutanea tarda.

Porphyria cutanea tarda (PCT) is a clinical manifestation of decreased uroporphyrinogen decarboxylase (UPD) activity. Multiple endogenous and exogenous factors have been implicated in inducing PCT in genetically predisposed patients. The most recent is the RNA virus hepatitis C (HCV), which is transmitted via blood exposure. The mechanism of action in HCV-induced PCT is unknown but produces the same clinical, laboratory, and histopathologic changes seen in other forms of sporadic PCT. Therefore, patients presenting with PCT clinically should be tested serologically for antibodies against HCV and patients with HCV should be monitored for signs and symptoms of PCT.

Adult↗